Volume 39, 1993 AUTHOR INDEX - Clinical Chemistry

More documents

Recommendations

Info

Calibration characterization procedure for ion-selective electrode assays of Mg acty. in aq. solne. of physiological compoeition(SN), 855 IFCC standarization project for mess, of apes A-I and III. Comparability of ape A-I values by unternatl. ref. material, 773 intra- and intarlab. quality control for assay of amino acids in biol. fluids: 14 years of French experience, 1831 Calinodulin glycated calmodulin from platelets as index of glycemic control, 815 interference of lysophosphatidylchohne in hormone RIAs(SN), 865 CA M28 ci utility and validation of emerging biocham, markers for mammary adenocarcinoma(S), 2386 CA M29 cm. utility and validation of emerging biochem. markers for mammary adenocarcinoma(S), 2386 Cancer See also specific cancer-, Tumor markers anal, performance goals for mess. PSA(S), 1525 behavior of tumor markers CA19. 9, CA195, CAM43, CA242, and TPS in diag. and follow-up of pancreatic cancer, 420 cancer screening-tumor markere(A), 1114 carotenoids and other antioxidants in oral cancer(A), 1311 cervical cancer, human papillomavirus and folic acid(A), 1311 circadian pharmacodynamics of anticancer therapies(S), 2413 din. and lab, studies of a new IRMA of PTHrelated protein, 414 cm. appln, of PCR in cancer and genetic die. testing(S), 709 ci, applna. of serum and tissue markers in malignant die.: breast cancer as paradigm(S), 2404 develop, of ELISA for datn, of cancer procoagulant(A), 1186 enzyme immunoassay of liver-type arginasa and potential ci. appln., 794 avaln. of colorectal cancer- assocd, mucin CA M43 assay in serum(SN), 1029 FDA’s perspective on evaln. of tumor marker tests(S), 2439 gene mutations aid cytological screening of cancer(S), 708 genetic anal, of coloractal cancer(A), 1106 genomic components of carcinoganesis(S), 2375 growing use of nonisotopic CA 19-9 immunoassays increases between-lab. variability(L), 909 ‘hot spots” mutation anal. of53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites(SN), 2186 increased urinary excretion of pyridinium cross-links in cancer patients, 614 modeling response to anticancer drugs(A), 1109 models of neoplasia and their diagnostic implications: a historical perspective(S), 2360 monitoring CA 125 in serum of ovarian cancer patients administered 1811 -labeled F(ab’)2 fragments of 0C125 antibody(SN), 891 overview of chemoprevention strategies and drug devalop.(A), 1311 perspectives on future of cancer markers(S), 2444 practical approaches to molecular screening of cancer: the colon cancer model(A), 740 prelim. evaln. of TPS IRMA in patients with cancer(A), 1194 prevalence of antibodies against p53 protein in various cancars(A), 1192 primary aldosteronism in a patient with aldosterone-producing adenoma(CR), 1729 programming events in regulation of cell prolif. and death(S), 356 progress in gene therapy(S), 705 PSA biochem,, anal, methods, and cm. appln.(R), 181 PSA and prostate vol.: screening algorithms(A), 1148 reimbursement of tumor marker tests(S), 2435 screening for cancer: cost affective?(S), 2397 serum phospholipasas A2 in inflammatory dis.(R), 2453 serum tumor markers for patient monitoring: case-oriented approach illustrated with CEA(S), 2431 study of neoplastic enzyme patterns by flow cytometry(A), 1194 therapeutic drug monitoring in cancer management(S), 2419 TPS in discriminating between superficial and invasive transitional call carcinoma of bladder(A), 1186 vitamin D, Ca, and colon cancer(A), 1311 Cannablnolda evaln. of Syva II cannabinoid assays on Olympus Reply Analyzer(A), 1231 performance of Emit 1120,50, and 100 ng cannabinoid assays(A), 1232 Carbamazepine CEDIA carbamazepina assay on Boehringer MannheimlHitachi 704 and 717 analyzers: multicenter avaln.(A), 1201 direct sample anal, of carbamazepine in serum by shielded hydrophobic phase liq. chromatog.(A), 1237 Carbon dioxide aberrant J02 in proficiency testing, 467 methods comparison of CO2 detn.(A), 1215 Carbonic anhydrase competitive time-resolved immunofluorometric assay for quantifying carbonic enhydrase VI in saliva(SN), 2154 Carboplatin therapeutic drug monitoring in cancer management(S), 2419 Carcinoembryonic antigen eveln. of chemiluminescenca method (ACS:180) for CEA(A), 1192 evain. of CEA assayed on Ciba Corning ACS: 180 chamiluminescent immunoanalyzer(A), 1189 evaln. of colorectal cancar-assocd. mucin CA M43 assay in serum(SN), 1029 evaln. of imniunoaasay system (IMx) for CEA(A), 1187 high-molecular-mass ALP as a tumor marker for colorectal cancer: comparison of 2 test methods(SN), 540 interpretation of results for tumor markers on the basis of anal, imprecision and biol. variation, 2077 modified method for daig. CEA in presence of human anti-murine antibodies(SN), 522 serum and tissue CEA expression in patients with previously reeected colon neoplasias(A), 1194 serum tumor markers for patient monitoring: case-oriented approach illustrated with CEA(S), 2431 Cardiovascular disease See also Heart disease albuminuria in people at least 40 years old: effect of alcohol consumption, regular axcercise, and cigarette smoking, 1793 redox status and protein binding of plasma aminothiols during transient hyperhomocystainemia that follows homocyeteine administration, 980 Carnitine carmtine meas. in liver, muscle tissue, and blood in normal sulects, 592 Carotenes sepn. of 13-carotene and lycopena geometrical isomers in biol. samples, 810 Carotenolde carotanoids and other antioxidants in oral cancer(A), 1311 reported effects of long-term storage on concs. of retinol, Il-carotene, and a-tocopherol in serum or plasma summarized(SN), 1075 sepn. of 13-carotene and lycopene geometrical isomers in biol. samples, 810 simult, detn, of vitamins A and E and carotenoids in plasma by reversed-phase HPLC in elderly and younger subjects, 2229 Casein kinase antibodies to casain kinase n in sara of patients with mixed connective tissue dis.: avaln. with recombinant proteins(SN), 2492 Case Conference ci, chem. lab, and acute pancreatitis (Washington University Case ConfarenceXCC), 234 Case Reports childhood perphyrias: implications and treatmanta(CR), 1334 early diagnosis of ectopic arginine vasopressin sacretion(CR), 152 factitious hyparthyroxinamia due to monoclonal IgA in a case of multiple myeloma(CR), 1739 3-hydroxydicarboxylic and 3.ketodicarboxylic aciduria in 3 patients: evidence for new defect in fatty acid oxid, at level of 3-ketoacyl-CoA thiolase(CR), 897 pelyclonal free light chains interfere with identn. of Bence Jones proteins(CR), 1734 primary aldosteronism in patient with aldostarone-producing adenoma(CR), 1729 severe isopropanolemia without acatonamia or ci. manifestations of isopropanol intoxication(CR), 1922 transferrin allelic variants may cause false poe. in detect. CSF fistulae(CR), 1444 Catalase mechanism of fructosemine assay: evidence against role of euperoxida dismutase as intermediate in nitroblue tetrazolium reduction, 2460 Catecholamines data, of matanephrinas in plasma by liq. chromatog. with electrocham. detect,, 97 meas, of catecholamines by diphenylborinicl C15 solid phase axtn, followed by HPLC and alactrochem. detact.(A), 1162 optimal collection and storage conditions for catecholamine in plasma and urine(SN), 2503 urinary excretion of catecholamine matabolites by children with acute lymphoblastic leukamia(A), 1191 urinary excretion of catecholamine matabolites by children with hepatoblsstoma(A), 1193 Cathepsin. assay of complexad a1-antichymotrypain in plaama(SN), 869 din, applns. of serum and tissue markers in malignant dis.: breast cancer as paradigm(S), 2404 in vitro effect of elastasa and cathepsin G from human neutrophils on CK and LDH isoenzymas, 986 Cat scratch disease EIA for detect, of Rochalimaea hesselae-reactive IgG, 1gM, and IgA Abe in patients with cat scratch dis.(A), 1260 Rochalimaea henselae infection: cause of CNS complications in A1DS(A), 1149 seroprevalenca of Roclsalimaea kenselae in HIlT pea. patients with adenopathy(A), 1139 cDNA amplification and sequencing of fragment of human glutaminyl cyclasa cDNA(A), 737 recombinant CK proteins and proposed stds. for CK isoenzyma and subform assays, 1598 CEDIA anal, of myeloma patients’ specimens by CEDIA5, 701 appln. of CEDIA Digoxin Plus reagent to Beckman Synchron CX4, XC5, and CX7 systems(A), 1229 appln. of Microgenics CEDIA ferritin assay to Olympus Reply(A), 1257 CEDIA carbamazepine assay on Boehringer Mannheim/Hitachi 704 and 717 analyzers: multicenter evaln.(A), 1201 avaln, of 3 CEDIA TDMs on BM/Hitachi 911(A), 1236 CLINICAL CHEMISTRY, Vol. 39, No. 12, 1993 2577
Celise disease increased concs. of fecal anti-gliadin IgA antibodies in untreated celiac dis.(L), 696 xylose, anti.gliadin, and anti -endomysium antibodies in adult caliac dis.(L), 1753 Cell adhesion molecules behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in diag. and follow-up of pancreatic cancer, 420 Cell cycle programming events in regulation of cell prolif. and death(S), 356 Cell-mediated immunity urinary neopterin as predictive marker of coronary artery abnormalities in Kawasaki syndrome, 600 Centrifugal analyzer assay instrument-dependent matrix effects in standardization of cholesterol mess., 2058 automated spectrophotometric method for detg. oxidized and reduced glutathione in liver(SN), 686 cysteine protainasa acty. in synovial fluids measd. with oentrif analyzer(L), 1751 phanylalanine deed. in plasma with use of phenylalanine dehydrogenase and a centriL analyzer(SN), 129 Cerebro.pinal fluid evain, of Baxter Paramex tableted reagent for detn. of CSF protein(A), 1213 avain, of CSF as a sample type for lactate anal, on Beckman Synchron CX7(A), 1211 isocratic HPLC assay with electrochem. detect, of free ‘‘aminobutyric acid in CSF(SN), 247 methemoglobin detns, in CSF have low cha. utility(L), 920 performance of Kodak Ektachem cha. chem. slides (uric), (phos), and (lac) in anal, of uric acid and P04 in urine and lactate in CSF(A), 1178 radioligand assay for biotin in CSF(A), 1275 ref. values for CSF albumin, IgG, IgA, and 1gM and their appln. in diagnosing inflammatory neurol, disorders(A), 1263 time-resolved fluoroimmunoassay of 13-microglobulin in serum and CSF(L), 552 time-resolved immunofluorometric assay of complement C3: appln, to CSF(SN), 309 tranaferrin allelic variants may cause false poe. in detect. CSF fistulae(CR), 1444 Ceruloplasntin assessment of Cu status: effect of age and gender on ref. ranges in healthy adulte(SN), 883 Chagsz’ disease Chagasic Al, positive blood donor prevalence in U.S., Hispanic surname pepulations(A), 1246 diagnosis of Chagas’ disease with recombinant antigens of Ttypasosoma cnizi (A), 1249 Cheroot-Marie-Tooth disease quant. mess, of duplicated DNA as diagnostic test for Charcot-Marie-Tooth dis, type is, 1845 Chemiluminescence automated chemilumineecence assay for breast cancar(A), 1195 automated chemiluminescence assay for digoxin(A), 1256 automated chemiluminescenca assay for estradiol(A), 1163 automated chemiluminescent assay for folate on Access immunoassay system(A), 1271 automated chemiluminascent assay for quant. of IgE(A), 1267 chemiluminescence receptor assay for vitamin B12 , avidin bead capture(A), 1146 chemiluminescent assay for troponin-T using Enzymun-Test reagents(A), 1258 Ciba-Corning ACS: 180 folate assay vs Bio-Rad Quantiphase anal. (A), 1253 Ciba-Corning ACS: 180 folate assay, comparison to Becton Dickinson Simultrac-S folate(A), 1254 enhanced chamiluminescence essay for CA 19-9 using Enzymun.Test reagenta(A), 1191 2578 CLINICAL CHEMISTRY, Vol. 39, No. 12, 1993 enhanced chemilumineacence assay for CA 72-4 using Enzymun-Test reagents(A), 1190 enhanced chemiluminescenca assay for CA 125 using Enzymun-Test reagenta(A), 1193 evaln, of CEA assayed on Ciba Corning ACS: 180 chemiluminescent inimunoanalyzer(A), 1189 evain, of chemiluminescence method (ACS: 180) for CEA(A), 1192 evaln. of Ciba Corning automated chemilumineacenca system for total IgE quant. assay(A), 1210 evaln, of PSA on Ciba Corning ACS:180 chemiluminescent analyzar(A), 1186 fast, manual, nonradioactive method for DNA aequencing(SN), 1682 improved chemiluminescant DNA sequencing: evaln, of multiplex labeling, direct transfer electrophoresis, and CCD camera detect. technologies(A), 740 multiple forms of PSA in serum: variances in immunorecognition between monoclonel and polyclonal assays, 2483 new reagents for chemiluminescant detect. single copy genes(A), 741 transcriptionally amplified DNA probe assay with ligatable probes and immunochemical detect.(S), 1934 Chemiluminescence lmmunoassay acridinium ester labeled chemiluminescence immunoassay for ACTH(A), 1260 acridinium ester-labeled chamiluminescance immunoassay for anti-thyroglobulin autoantibodiee(A), 1274 acridinium ester-labeled chamiluminescence immunoassay for anti-thyroid peroxidase autoantibodiea(A), 1272 automated chemiluminescance immunoasaay for progesterone(A), 1259 automated chemiluminescence immunoassay for total hCG(A), 1261 automated chemiluminescant assay for prolactin on Immulite system(A), 1262 automated chemilumineecant iminunoassay for theophyllina(A), 1240 automated PSA immunoassay for Immulite chemiluminascent assay(A), 1264 chemiluminescence immunometric assay for erythropeietin(A), 1248 chemiluminescent assay to detect antibodies to RNP(A), 1139 chemilumineacent assays for detect. of antibodies to La and Ro(A), 1140 chemiluminescent immunoassay for detn, of FSH(A), 1163 enhanced chemiluminescance labeled Ab immunoassay for FT4 (Amerlite Mab FF4 kitXA), 1268 avaln. chamiluminescent immunoassay for IgE(A), 1132 free T3 by equilibrium dialyeis/. chemilumineecent immunoassay(A), 1262 osteocalcin chemiluminoimmunoassay, 1369 third-generation method for TSH(A), 1261 third-generation TSH immunoassay on Immunlite chemiluminesoent immunoassay system(A), 1260 Chemilumlnescent enzyme immunoassay chemiluminescent enzyme immunoessay for endothelin- 1(A), 1247 chemiluminascent enzyme immunoassay for human LH(A), 1165 Chemometric. characterization procedure for ion-selective electrode assays of Mg acty. in sq. solns, of physiological composition(SN), 855 ionized Mg mess, in serum(A), 1176 Chiamydla STCChOmOtI. molecular film fluorescence technology appld. to detect. Chiamydia Irachomatis LPS(A), 1257 Chloride comparison of hypertonic and isotonic ref. electrode junctions for mess, ionized Ca in whole blood: cha. study(SN), 1082 improved correlation of sweat chloride quantn. by CF indicator system and the Gibson-Cooke sweat test(L), 1748 ionic binding, net charge, and Donnen effect of human serum albumin as a function of pH, 48 Chlorpromazine estn. of plasma and urinary Hb by rate spectrophotometric method(SN), 1679 Cholesterol AccuMeter noninetrumented quant. assay of HDL in whole blood(S), 1948 assay instrument-dependent matrix effects in standardization of cholesterol meas., 2058 assessment of HDL cholesterol in hypertriglyceridemic sera(L), 1350 biol, variability in conc., of serum lipids: sources of variation among results from published studies and composite predicted values, 1012 candidate ref. methods for daig. target values for cholesterol, creatina, uric acid, and glucose in external quality assessment and internal accuracy control. I. Method setup, 993 candidate ref. methods for data. target values for cholesterol, creatine, uric acid, and glucose in external quality assessment and internal accuracy control. II. Method transfer, 1001 coronary artery disease risk predicted by plasma concs. of HDL cholesterol, ape Al, ape B, and Lp(a) in general Chinese population, 209 dietary nutrient intakes and slight albuminuria in people at least 40 years old(SN), 2191 effect of thyroid function on concs. of Lp(a), 2466 electrophoretic quanta. LDL-cholesterol using Helena REP(A), 1122 elevated HDL-cholesterol by phosphotungstate ppt.(A), 1125 evalg. human serum based LDL cholesterol bi-lavel control using Genzyme’s immunoaepn. reagent(A), 1126 evaln, of 7 Cholestech L.D.X analyzers for total cholesterol detns.(SN), 860 evain. of Genzyme immunosepn. reagent for quan. LDL cholesterol(A), 1124 evaln. of Novochol reagent for measuring cholasterol(A), 1127 evaln, performance criteria for cm. labs, in cholesterol ref. method lab. network(A), 1123 fast lipoprotain chromatog.: new method of anal, for plasma lipoproteins, 2276 Friedaweld’s formula re-evald.(A), 1128 HDL-cholesterol assay, on Kodak Ektachem D’F60 II, 250, 500, and 700 analyzers compared with CDC Network Ref. Lab.(A), 1126 HDL-cholesterol: online sepn. and anal. using automated analyzer(A), 1125 interference of lysophosphatidyicholine in hormone RIAa(SN), 865 lipid and lipoprotein levels in children and adolescents(A), 1123 microaffinity chromatog. sepn. and characterization of lipoprotein fractions in rat and Mongolian gerbil serum(SN), 1861 modifn, of dextran-Mg’ HDL cholesterol pptn. method(A), 1121 multicenter evain. of Reflotron direct dry-chemistry assay of RDL cholesterol in venous and fingarstick specimans(SN), 271 NCEP certification of traceability for new Olympus cholesterol reagent(A), 1121 nonlinearity of HDL-cholesterol detn, is matrix dependent(A), 1120 polymorphism of ape E, Lp(a), and other lipoproteins in children with type I diabetea(SN), 1427 prediction of alcohol-related harm by lab. test results, 2266 relation of Lp(a) in 11- to 19-year-old adolescents to parental cardiovascular heart disease, 477 serum cholesterol detd. by liq. chromatog. with 6-chloroetigmasterol as internal std., 1602 total error assessment of 5 methods for cholesterol screening (SN), 297
Page 1 and 2: llfiill Journal of the American Ass
Page 3 and 4: Blanc, Jennifer A.; Manneh, Victor
Page 5 and 6: Conn, Rex B.(health care reform and
Page 7 and 8: Feldbruegge, Donald H. See Ringelst
Page 9 and 10: Hallworth, Mike; Petchey, Michael D
Page 11 and 12: Jones, R.G.; Purves, D.; Cooper, E.
Page 13 and 14: -; Galbraith, Linda V.; Bradley, Co
Page 15 and 16: Middelkoop, Cornelis M.; Bekker, Gu
Page 17 and 18: -; Ward, Patrick J.; Tuckerman, Jam
Page 19 and 20: Samsonov, Mikhail; Nassonov, Eugane
Page 21 and 22: Strand, Gary A.; McVey, Walter B. J
Page 23 and 24: Wald, 1115 Nicholaa(scneening, Down
Page 25 and 26: A, abstract of meeting paper CR, ca
Page 27 and 28: selective removal of -microglobulin
Page 29: hapten-heterologous conjugates eval
Page 33 and 34: phenol and p-cresol in uremic serum
Page 35 and 36: CeO and metabolite binding to cyclo
Page 37 and 38: Elastase differences in elastese-bi
Page 39 and 40: 10-mm microplate ELISA for data. of
Page 41 and 42: Formaldehyde colonimetric assay of
Page 43 and 44: Heme fully automated assay of Glib
Page 45 and 46: hepatic and lipoprotein lipases sel
Page 47 and 48: Insulin adaptation of TOSOH IRI ass
Page 49 and 50: lipase in serum-elusive enzyme: an
Page 51 and 52: Microwaves microwave-induced rapid
Page 53 and 54: Ovary tissue-specific promoters reg
Page 55 and 56: simple economic method for directly
Page 57 and 58: RIA for pyridinoline cross-linked c
Page 59 and 60: platelet serotonin content and free
Page 61 and 62: Thyroliberin equivalent discriminat
Page 63 and 64: how and how long to store urine sam
Page 65 and 66: January:pages 1 - 178 February:page
Page 67: -an#{231}&tfedcI yea #{149} oizais4

Volume 39, 1993 AUTHOR INDEX - Clinical Chemistry

Create successful ePaper yourself

Delete template?

Save as template?